Press Release – For immediate Release – 5:45 pm CET
Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to TP ICAP (Europe), the following resources were listed in the liquidity account as of 12/29/2023:
- 28,228 shares
- €106,617.89 in cash
During the second half of 2023, it has been traded a total of:
| BUY | 96,229 Shares | EUR 457,244.45 | 338 transactions |
| SELL | 96,971 Shares | EUR 461,187.31 | 273 transactions |
At the time of the half-yearly statement of 06/30/2023, the following resources were included in the liquidity account:
- 28,970 shares
- €105,784.53 in cash
When the new liquidity contract was put in place on 05/04/2020, the following resources were made available:
- 4,404 shares
- € 173,829.64 in cash
The daily transaction table is provided in the pdf version of the press release.
TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit